TILRAY BRANDS INC (TLRY.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:TLRY - US88688T1007 - Common Stock
10.17 CAD
+0.12 (+1.19%)
Taking everything into account, TLRY scores 2 out of 10 in our fundamental rating. TLRY was compared to 31 industry peers in the Pharmaceuticals industry. TLRY may be in some trouble as it scores bad on both profitability and health. TLRY is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TLRY had negative earnings in the past year.
In the past year TLRY has reported a negative cash flow from operations.
In the past 5 years TLRY always reported negative net income.
In the past 5 years TLRY reported 4 times negative operating cash flow.
1.2 Ratios
TLRY has a worse Return On Assets (-103.13%) than 83.87% of its industry peers.
TLRY's Return On Equity of -139.41% is on the low side compared to the rest of the industry. TLRY is outperformed by 77.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -103.13% | ||
| ROE | -139.41% | ||
| ROIC | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TLRY has a Gross Margin of 28.69%. This is comparable to the rest of the industry: TLRY outperforms 45.16% of its industry peers.
In the last couple of years the Gross Margin of TLRY has grown nicely.
TLRY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.69% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TLRY has more shares outstanding
The number of shares outstanding for TLRY has been increased compared to 5 years ago.
The debt/assets ratio for TLRY is higher compared to a year ago.
2.2 Solvency
TLRY has an Altman-Z score of -1.79. This is a bad value and indicates that TLRY is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TLRY (-1.79) is worse than 67.74% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that TLRY is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.18, TLRY is in line with its industry, outperforming 54.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.79 |
ROIC/WACCN/A
WACC7.97%
2.3 Liquidity
A Current Ratio of 2.62 indicates that TLRY has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.62, TLRY is in the better half of the industry, outperforming 61.29% of the companies in the same industry.
TLRY has a Quick Ratio of 1.56. This is a normal value and indicates that TLRY is financially healthy and should not expect problems in meeting its short term obligations.
TLRY's Quick ratio of 1.56 is fine compared to the rest of the industry. TLRY outperforms 67.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.56 |
3. Growth
3.1 Past
TLRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -6498.00%.
The Revenue has been growing slightly by 2.31% in the past year.
Measured over the past years, TLRY shows a very strong growth in Revenue. The Revenue has been growing by 37.52% on average per year.
EPS 1Y (TTM)-6498%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)2.31%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
3.2 Future
TLRY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.94% yearly.
Based on estimates for the next years, TLRY will show a small growth in Revenue. The Revenue will grow by 4.31% on average per year.
EPS Next Y99.61%
EPS Next 2Y41.34%
EPS Next 3Y25.98%
EPS Next 5Y14.94%
Revenue Next Year3.65%
Revenue Next 2Y4.08%
Revenue Next 3Y4.24%
Revenue Next 5Y4.31%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TLRY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLRY. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
TLRY's Enterprise Value to EBITDA is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 20.21 |
4.3 Compensation for Growth
A more expensive valuation may be justified as TLRY's earnings are expected to grow with 25.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.34%
EPS Next 3Y25.98%
5. Dividend
5.1 Amount
No dividends for TLRY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:TLRY (12/5/2025, 7:00:00 PM)
10.17
+0.12 (+1.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners10.33%
Inst Owner ChangeN/A
Ins Owners0.36%
Ins Owner ChangeN/A
Market Cap1.18B
Revenue(TTM)830.77M
Net Income(TTM)-2.15B
Analysts71.25
Price Target23.95 (135.5%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2631.48%
Min EPS beat(2)-5362.97%
Max EPS beat(2)100%
EPS beat(4)1
Avg EPS beat(4)-1385.84%
Min EPS beat(4)-5362.97%
Max EPS beat(4)100%
EPS beat(8)2
Avg EPS beat(8)-708.23%
EPS beat(12)2
Avg EPS beat(12)-746.7%
EPS beat(16)4
Avg EPS beat(16)-606.4%
Revenue beat(2)1
Avg Revenue beat(2)-3.41%
Min Revenue beat(2)-7.23%
Max Revenue beat(2)0.41%
Revenue beat(4)1
Avg Revenue beat(4)-6.19%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)0.41%
Revenue beat(8)1
Avg Revenue beat(8)-5.71%
Revenue beat(12)2
Avg Revenue beat(12)-3.59%
Revenue beat(16)2
Avg Revenue beat(16)-3.93%
PT rev (1m)805.82%
PT rev (3m)1665.52%
EPS NQ rev (1m)-900%
EPS NQ rev (3m)-788.89%
EPS NY rev (1m)-19.05%
EPS NY rev (3m)54.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.01%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)-0.15%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.02 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.55 | ||
| P/tB | 1.11 | ||
| EV/EBITDA | 20.21 |
EPS(TTM)-18.39
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS9.98
BVpS18.51
TBVpS9.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -103.13% | ||
| ROE | -139.41% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.69% | ||
| FCFM | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
F-Score3
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 6.5 | ||
| Cap/Depr | 30.45% | ||
| Cap/Sales | 4.3% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.56 | ||
| Altman-Z | -1.79 |
F-Score3
WACC7.97%
ROIC/WACCN/A
Cap/Depr(3y)21.23%
Cap/Depr(5y)65.01%
Cap/Sales(3y)3.68%
Cap/Sales(5y)7.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6498%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y99.61%
EPS Next 2Y41.34%
EPS Next 3Y25.98%
EPS Next 5Y14.94%
Revenue 1Y (TTM)2.31%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
Revenue Next Year3.65%
Revenue Next 2Y4.08%
Revenue Next 3Y4.24%
Revenue Next 5Y4.31%
EBIT growth 1Y28.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.61%
EBIT Next 3Y29.12%
EBIT Next 5Y17.36%
FCF growth 1Y-688.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-258.17%
OCF growth 3YN/A
OCF growth 5YN/A
TILRAY BRANDS INC / TLRY.CA FAQ
Can you provide the ChartMill fundamental rating for TILRAY BRANDS INC?
ChartMill assigns a fundamental rating of 2 / 10 to TLRY.CA.
What is the valuation status of TILRAY BRANDS INC (TLRY.CA) stock?
ChartMill assigns a valuation rating of 1 / 10 to TILRAY BRANDS INC (TLRY.CA). This can be considered as Overvalued.
How profitable is TILRAY BRANDS INC (TLRY.CA) stock?
TILRAY BRANDS INC (TLRY.CA) has a profitability rating of 1 / 10.
How financially healthy is TILRAY BRANDS INC?
The financial health rating of TILRAY BRANDS INC (TLRY.CA) is 3 / 10.